Therini Bio

Therini Bio is a Sacramento-based clinical-stage biopharmaceutical company founded in 2019 by Katerina Akassoglou, a professor at UCSF and senior investigator at the Gladstone Institutes. The company's science is based on the discovery that a cryptic epitope on fibrin (a blood-clotting factor) drives chronic innate immune activation and neurodegeneration when fibrin leaks outside blood vessels into brain tissue. Its lead candidate THN391 is a monoclonal antibody that selectively targets this inflammatory fibrin epitope to block microglial and macrophage activation. THN391 completed a Phase Ia trial in healthy volunteers in 2025, demonstrating tolerability. A $39M Series A extension in May 2025 (with Angelini Ventures) will fund a Phase Ib trial for THN391 and development of a fibrin/VEGF bispecific for retinal diseases. Total raised is approximately $62M+ with backing including Eli Lilly.